Adalimumab - Localised Psoriasis
You are here : Home > Formulary Search > Adalimumab - Localised Psoriasis
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
PAD Profile
ChemicalSubstance :
Adalimumab
Indication :
Localised Psoriasis
Group Name :
Keywords :
Biologic, immunosuppressant, Cytokine modulator, TNF Alpha Inhibitor, DMARD, bDmard, Disease modulating, Dermatology, biosimilar, high impact sites, PGA, Physicians Global Assessment
Brand Names Include :
Humira, Hyrimoz, Imraldi, Amgevita, Hulio, Yuflyma, Idacio
Important Information :
Dermatology specialist team only.
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Committee Recommendations (1)
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agree the following immunomodulators for use in localised psoriasis
- Etanercept
- Infliximab
- Adalimumab
- Ustekinumab
- Secukinumab
- Ixekizumab
- Certolizumab
- Guselkumab
For use in the following body areas
• Head and neck – includes face and scalp
• Nails
• Genitals
• Hands and feet
• Flexures
These are all RED drugs, and the Dermatology teams will complete Blueteq forms for initiation and continuation.
Other Indications
Below are listed other indications that Adalimumab is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Localised Psoriasis.